BioInvent International AB (BOVNF)
OTHER OTC:BOVNF
Want to see BOVNF full AI Analyst Report?
BOVNF Stock Chart & Stats
$3.29
$0.00(0.00%)
At close: 4:00 PM EDT
$3.29
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.77 - $3.77
Previous CloseN/A
Volume3.00
Average Volume (3M)0.00
Market Cap
$193.18M
Enterprise Value$1.46B
Total Cash (Recent Filing)$456.48M
Total Debt (Recent Filing)$6.25M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Aug 27, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding65,804,360
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market Cap7.56
Enterprise Value/Revenue6.70
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda-4.47
Forecast
1Y Price Target
$9.61Price Target Upside192.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$30.07M
Bulls Say, Bears Say
Bulls Say
Clinical-stage Pipeline EfficacyHigh response rates and durable responses in CTCL, plus an EMA orphan designation, materially de-risk the BI-1808 program. Orphan status and durable CRs improve regulatory/pathway options, enhance partner interest, and strengthen long-term commercial and development prospects beyond short-term variability.
Strategic Collaborations With Large PharmaPartnerships with Merck and AstraZeneca provide clinical combo drugs, operational support and external validation. These collaborations lower development execution risk, can fund portions of trials, and increase chances for milestone/royalty revenue and successful transitions to later‑stage or commercial partnerships.
Low Financial LeverageMinimal debt reduces refinancing and interest burdens, preserving flexibility to structure partner deals or raise equity without near‑term solvency pressure. This stronger balance sheet positioning supports sustained clinical development even while the company completes financing or partnership milestones.
Bears Say
Persistent Negative Cash Flow And BurnConsistent negative operating and free cash flow means the company must repeatedly access external capital or partner funding to sustain trials. Large burn (~-260M) relative to revenue heightens dilution and execution risk, limiting ability to self‑fund pivotal programs if data or deals are delayed.
Revenue Reliant On One-time ItemsRevenue growth was driven by non-recurring payments while recurring production revenue fell, creating an unstable top‑line. This volatile revenue mix weakens internal funding capacity for sustained program spending and increases reliance on milestone deals or equity raises for long‑term operations.
High Execution And Regulatory Bar For Pivotal StartsA demanding efficacy threshold and pending regulatory discussions mean pivotal advancement is conditional on strong upcoming readouts. Failure to meet benchmarks would delay pivotal starts, reduce partner appetite and complicate fundraising, materially affecting multi‑year development timelines and commercial prospects.
BioInvent International AB News
BOVNF FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was $2.77 and its highest was $3.77 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is $193.18M.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Aug 27, 2026 which is in 95 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Apr 29, 2026. The company reported -$0.202 earnings per share for the quarter, the consensus estimate of -$0.202 by $0.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Undervalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate is -0.2.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -$0.202 in its last earnings report, expectations of -$0.202. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in BOVNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
BOVNF Company Deck
BOVNF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.View all BOVNF earnings summariesBOVNF Stock 12 Month Forecast
Average Price Target
$9.61
▲(192.02% Upside)
Technical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
― Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---